(Reuters) - Novartis said it now expected mid-single-digit growth in
group net sales and low-single-digit growth in drug sales,
slightly lower than its previous outlook.
Net profit at Novartis from continuing operations rose 18
percent to $1.94 billion in the second quarter due to strong
sales of top-selling drugs Diovan and Glivec and in line with
analysts' forecasts.
Read more at Reuters.com Mergers News
group net sales and low-single-digit growth in drug sales,
slightly lower than its previous outlook.
Net profit at Novartis from continuing operations rose 18
percent to $1.94 billion in the second quarter due to strong
sales of top-selling drugs Diovan and Glivec and in line with
analysts' forecasts.
Read more at Reuters.com Mergers News
No comments:
Post a Comment